ESR2 多态性与前列腺癌风险：系统评价和荟萃分析。
ESR2 polymorphisms on prostate cancer risk: A systematic review and meta-analysis.
机构信息
Department of Urology, The Second Hospital of Hebei Medical University, Shijiazhuang, China.
出版信息
Medicine (Baltimore). 2023 Jun 9;102(23):e33937. doi: 10.1097/MD.0000000000033937.
BACKGROUND
This meta-analysis was performed to address the association of 2 ESR2 gene polymorphisms (rs1256049 and rs4986938) with susceptibility to cancer.
METHODS
An extensive literature search for eligible candidate gene studies published before May 10, 2022, was conducted in PubMed, Medline, and Web of Science. The search strategy was as follows: (ESR2 OR ERβ OR ER beta OR estrogen receptor beta) AND (polymorphism OR mutation OR variation OR SNP OR genotype) AND (PCa OR PC OR prostate cancer). Potential sources of heterogeneity were sought out via trial sequential analysis, subgroup, and sensitivity analysis.
RESULTS
Overall, a total of 10 articles involving 18,064 cases and 19,556 controls for 2 polymorphisms of the ESR2 gene were enrolled. In the stratified analysis of rs1256049, we found that Caucasians might be correlated with an increased risk of prostate cancer (PCa), while less susceptibility was found in Asians. We observed that rs4986938 was not associated with PCa risk.
CONCLUSION
ESR2 rs1256049 polymorphism is associated with a higher risk of PCa in the Caucasian population and a lower risk of PCa in the Asian population.
背景
本荟萃分析旨在探讨 2 个 ESR2 基因多态性（rs1256049 和 rs4986938）与癌症易感性的关联。
方法
在 PubMed、Medline 和 Web of Science 上进行了广泛的文献检索，以查找截至 2022 年 5 月 10 日发表的合格候选基因研究。搜索策略如下：（ESR2 或 ERβ 或 ER beta 或雌激素受体β）和（多态性或突变或变异或 SNP 或基因型）和（PCa 或 PC 或前列腺癌）。通过试验序贯分析、亚组和敏感性分析寻找潜在的异质性来源。
结果
总体而言，共纳入了 10 项研究，涉及 ESR2 基因的 2 个多态性，共纳入了 18064 例病例和 19556 例对照。在 rs1256049 的分层分析中，我们发现白种人可能与前列腺癌（PCa）的风险增加相关，而亚洲人则发现其相关性较低。我们观察到 rs4986938 与 PCa 风险无关。
结论
ESR2 rs1256049 多态性与白种人群中 PCa 的风险增加相关，与亚洲人群中 PCa 的风险降低相关。
Zotero 插件